[Eradication of Helicobacter pylori infection. A new therapy standard for duodenal ulcer].
Caspary
W F
WF
Medizinische Klinik II, Universitätsklinikum Frankfurt, Johann Wolfgang Goethe-Universität, Frankfurt/Main.
Braden
B
B
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate
Sanierung der Helicobacterpylori-Infektion. Ein neuer Therapiestandard für das Ulcus duodeni.